Opioid-Induced Constipation - Pipeline Insight, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 22, 2019--The “Opioid-Induced Constipation - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Opioid-Induced Constipation development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Opioid-Induced Constipation
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for Opioid-Induced Constipation
The report assesses the active Opioid-Induced Constipation pipeline products by developmental stage, product type, molecule type, and administration route.
Companies FeaturedDevelco Pharma Schweiz AG Ironwood Pharmaceuticals Inc. Shionogi & Co. Ltd. Sucampo Pharmaceuticals Inc. Synergy Pharmaceuticals Inc.
1. Report Introduction
2. Opioid-Induced Constipation Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical & Discovery Stage
7. Therapeutic Assessment
8. Inactive Products
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5hdmk4/opioidinduced?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190122005475/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Gastrointestinal Drugs ,Addiction Disorders Drugs
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/22/2019 06:52 AM/DISC: 01/22/2019 06:52 AM